Compare Peptides
Side-by-side comparisons of commonly confused or related peptides. See how they differ in evidence, safety, and use cases.
Not sure which peptide is right for your goals? Our comparison pages break down the differences between commonly compared peptides — from GLP-1 weight loss drugs like semaglutide vs tirzepatide to recovery peptides like BPC-157 vs TB-500, and broader comparisons like peptides vs steroids.
All Comparisons
BPC-157 vs TB-500
BPC-157 and TB-500 are two of the most commonly discussed recovery peptides. While they are both explored for tissue repair, they work through different mechanisms and have different evidence profiles. Understanding these differences can help inform conversations with your clinician about which might be more appropriate for your situation.
CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are frequently discussed together — and often used in combination — for growth hormone optimization. They work through complementary mechanisms, which is why the combination is one of the most popular peptide pairings. Understanding how each works individually helps explain why they are often paired.
Semax vs Selank
Semax and Selank are both Russian-developed nootropic peptides administered intranasally, but they target different aspects of brain function. Semax is primarily discussed for cognitive enhancement and neuroprotection, while Selank is focused on anxiety reduction and stress resilience.
GH Secretagogues: Tesamorelin vs CJC-1295 vs Sermorelin vs Ipamorelin
Growth hormone secretagogues are among the most popular peptides in the optimization space, but they differ significantly in mechanism, evidence base, FDA status, and clinical profile. Tesamorelin and Sermorelin are both GHRH analogs that stimulate GH release through the hypothalamic pathway, while Ipamorelin is a ghrelin-mimetic secretagogue, and CJC-1295 is a modified GHRH analog with an extended half-life. Understanding these distinctions is essential for informed conversations with your clinician about which approach best fits your goals.
GLP-1 Agonists: Semaglutide vs Tirzepatide vs Retatrutide
GLP-1 receptor agonists have transformed the weight management and metabolic health landscape. Semaglutide (Ozempic®/Wegovy®) was the breakthrough, Tirzepatide (Mounjaro®/Zepbound®) raised the bar with dual-agonism, and Retatrutide represents the next frontier as a triple agonist. All three reduce appetite and improve metabolic markers, but they differ meaningfully in mechanism, efficacy magnitude, side effect profiles, and regulatory status. This comparison helps you understand the evolving landscape.
Semaglutide vs Tirzepatide
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two most prescribed GLP-1 medications for weight loss and type 2 diabetes. The head-to-head SURMOUNT-5 trial settled the efficacy question — tirzepatide produces greater weight loss — but the choice between them involves cost, availability, tolerability, and individual response.
Peptides vs Steroids
Peptides and anabolic steroids are frequently confused but are fundamentally different classes of compounds. Steroids directly replace or augment hormones, while peptides signal the body to optimize its own production. Understanding these differences is important for anyone considering performance, recovery, or body composition interventions.
Peptides vs SARMs
Peptides and SARMs (Selective Androgen Receptor Modulators) are both discussed in performance and wellness communities, but they work through entirely different mechanisms. SARMs are essentially more targeted steroids — they activate androgen receptors selectively — while peptides are signaling molecules that work through non-androgenic pathways.
MK-677 vs CJC-1295 + Ipamorelin
MK-677 and the CJC-1295 + ipamorelin stack are the two most popular approaches to growth hormone optimization — but they differ fundamentally in administration (oral vs injectable), mechanism, selectivity, and side effect profile. This comparison helps clarify which approach might be more appropriate for different goals.
Ozempic vs Wegovy
Ozempic and Wegovy are both semaglutide — the same molecule, made by the same company (Novo Nordisk). The difference is the approved indication and dosing. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. This is one of the most searched peptide comparisons, and the confusion is understandable.
Melanotan I vs Melanotan II
Melanotan I and Melanotan II share a name, a mechanism category, and a nickname ("the tanning peptide") — but they are fundamentally different drugs with dramatically different safety profiles. One is FDA-approved with 1,000+ patients treated and zero melanoma events. The other is unapproved everywhere, widely sold on the gray market, and linked to documented melanoma case reports. Confusing them is a costly mistake.
Popular GH Peptide Protocols: Tesamorelin vs CJC-1295+Ipamorelin vs Sermorelin vs MK-677
If you're exploring growth hormone optimization, four approaches dominate the conversation: the FDA-approved Tesamorelin (the only GH secretagogue with a current US approval), the popular CJC-1295 + Ipamorelin injectable combination, historical Sermorelin monotherapy, and the oral alternative MK-677. They differ significantly in mechanism, evidence depth, convenience, side-effect profile, and cost. This comparison helps you understand the trade-offs between the four most-discussed protocols — not to prescribe one, but to inform conversations with a clinician about which fits your goals.
Wolverine vs GLOW vs KLOW Peptide Stacks
The Wolverine Stack, GLOW, and KLOW are three of the most-searched peptide blends in the recovery and skin-rejuvenation community. All three share the BPC-157 + TB-500 "repair backbone." GLOW adds GHK-Cu for collagen and skin remodeling. KLOW adds both GHK-Cu and KPV for added anti-inflammatory coverage. The differences matter — particularly for quality control, stability, and whether the peptides belong together in the same vial.
CJC-1295 with DAC vs CJC-1295 without DAC (Modified GRF 1-29)
"CJC-1295" is used loosely in the peptide space to refer to two related but pharmacologically distinct molecules. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog covalently linked via a maleimidopropionic acid spacer to serum albumin, giving it a multi-day half-life. CJC-1295 without DAC — which is more accurately called Modified GRF 1-29 or Mod GRF 1-29 — is the same 29-amino-acid sequence without the albumin-binding linker, clearing in about 30 minutes. They are often marketed under the same "CJC-1295" name and sold on adjacent shelves, but they produce fundamentally different GH exposure patterns and are used differently in clinical and biohacking protocols.
GHK-Cu vs AHK-Cu (Copper Peptides)
GHK-Cu and AHK-Cu are the two most-discussed copper peptides in cosmeceutical and hair-loss formulations. They share the same copper-binding architecture — a histidine-lysine C-terminus that coordinates a copper(II) ion — but they differ at the first amino acid (glycine vs alanine), and that single residue swap correlates with meaningfully different research profiles. GHK-Cu is the extensively studied skin and wound-healing copper peptide; AHK-Cu has a narrower, hair-focused evidence base. Despite the surface similarity, treating them as interchangeable overstates what the AHK-specific evidence actually supports.